Tadekinig alfa

他德白介素α

Report date: 2026/03/13 20:02:36

Base Information

Drug NameTadekinig alfa
Drug Alias Name部分白介素-18αRecombinant human IL-18 binding proteinTadekinigum alfar-hIL-18BPIL-18BP
ClassificationBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionInterferon gamma inhibitorsInterleukin-1 alpha inhibitorsInterleukin 18 inhibitors +[4] 
TargetsInterleukin 18Interferon gammaInterleukin-1 alpha +[4] 
Therapy Area/IndicationsMacrophage Activation SyndromeAutoimmune Lymphoproliferative SyndromeLymphohistiocytosis, Hemophagocytic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesGermany
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesAb2 Bio Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAb2 Bio LtdUniversity Of Pennsylvania
Inactive CompaniesN/A
Active IndicationsMacrophage Activation SyndromeAutoimmune Lymphoproliferative SyndromeLymphohistiocytosis, Hemophagocytic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A